Novel Therapeutic Approaches in the Treatment of Multiple Myeloma

Share article


Date: November 6, 2001
Location: Toronto, Canada


Symposium Web Page: www.multiplemyeloma.org/events/seminars.html

Sponsors: Multiple Myeloma Research Foundation and University of Toronto


News
ASH: Novel Drug Beneficial in Multiple Myeloma

Jul 22, 2014 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a high response rate and a low incidence of side effects, according to research presented at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More